Enfermedades Infecciosas y Microbiología Clínica

ISSN: 0213-005X

Indexed in:

Index Current Contents/Clinical Medicine, JCR, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, CANCERLIT, SCOPUS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

2.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.36

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.38

View more metrics

Journal Information

Back to article

Statistics

Follow this link to access the full text of the article

Original article

Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients

Dalbavancina como tratamiento de consolidación en endocarditis infecciosa: experiencia en vida real en pacientes añosos y comórbidos

Eduardo Aparicio-Minguijóna,1,

Corresponding author

edu.ap93@gmail.com

Corresponding author.

, Jorge Boána,1, Antonio Terróna, Carlos Herediaa, Cristina Puentea, Asunción Pérez-Jacoiste Asína, M. Ángeles Orellanab, Laura Domínguezc, José Manuel Carod, M. Jesús López-Gudee, Eva María Aguilar-Blancoe, Andrea Eixerés-Estevee, Francisco López-Medranof,g

a Department of Internal Medicine, University Hospital ‘12 de Octubre’, Spain

b Department of Microbiology, University Hospital ‘12 de Octubre’, Spain

c Department of Cardiology, University Hospital ‘12 de Octubre’, Spain

d Department of Pharmacy, University Hospital ‘12 de Octubre’, Spain

e Department of Cardiac Surgery, University Hospital ‘12 de Octubre’, Spain

f Unit of Infectious Diseases, University Hospital ‘12 de Octubre’, Instituto de Investigación Sanitaria Hospital ‘12 de Octubre’ (imas12), School of Medicine, Universidad Complutense, Madrid, Spain

g Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Spain

Read

486

Times
was read the article

138

Total PDF

348

Total HTML

Share statistics

Article information

ISSN: 0213005X
Original language: English

DOI:10.1016/j.eimc.2024.04.009

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 May	4	2	6
2025 April	5	2	7
2025 March	2	3	5
2025 February	126	68	194
2024 December	1	0	1
2024 November	1	2	3
2024 October	7	6	13
2024 September	7	2	9
2024 August	1	1	2
2024 July	7	8	15
2024 June	187	44	231

Follow this link to access the full text of the article

Publish in

Enfermedades Infecciosas y Microbiología Clínica

Free access articles

Outpatient parenteral antibiotic therapy (OPAT)...

Enferm Infecc Microbiol Clin. 2024;42:581-7

Corrigendum a: Ecografía clínica:...

Enferm Infecc Microbiol Clin. 2024;42:281

The current status of arboviruses with major...

Enferm Infecc Microbiol Clin. 2024;42:516-26

La Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica agradece la colaboración de:

SOCIOS PROTECTORES

SOCIOS PATROCINADORES

- Becton Dickinson S.A.U.
- Janssen-Cilag, S.A.
- Angelini Farmacéutica, S.A.
- Biomerieux España, S,A.U.
- Merck Sharp & Dohme de España, S.A.
- Hologic Iberia, S.L.U.
- Laboratorios Menarini S.A.
- Accelerate Diagnostics S.L.
- Abbott Laboratories, S.A.
- Cepheid Iberia S.L.U.
- Illumina Productos de España. S.L.U.
- DiaSorin Iberia, S.A.
- GlaxoSmithKline, S.A.
- Sysmex España S.L.

Enfermedades Infecciosas y Microbiología Clínica follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter